ANTI-CARM1 CLONE 2H11 ZOOMAB RABBIT MONOCLONAL (C15-1670-449)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 2H11 is a Rabbit recombinant monoclonal antibody that specifically detects Histone-arginine methyltransferase CARM1. It targets an epitope within 17 amino acids from the C-terminal half.

Immunogen

KLH-conjugated linear peptide corresponding to 17 amino acids from the C-terminal half of human Histone-arginine methyltransferase CARM1.

Application

Quality Control Testing

Evaluated by Western Blotting in PC3 cell lysate.

Western Blotting Analysis: A 1:1000 dilution of this antibody detected CARM1 in PC3 cell lysate.

Tested applications

Western Blotting Analysis: A 1:1000 dilution from a representative lot detected CARM1 in NIH3T3, HEK293, MCF-7, and PC12 cell lysates.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CARM1 (PRMT4) in human kidney tissue sections.

Immunocytochemistry Analysis: A 1:1000 dilution from a representative lot detected CARM1 in HeLa, A431, HepG2 and NIH3T3 cells.

Affinity Binding Assay: A representative lot of this antibody bound CARM1 with a KD of 2.9 x 10-7 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Histone-arginine methyltransferase CARM1 (UniProt: Q86X55; also known as EC:2.1.1.319, Coactivator-associated arginine methyltransferase 1, Protein arginine N-methyltransferase 4, PRMT4) is encoded by the CARM1 (also known as PRMT4) gene (Gene ID: 10498) in human. CARM1 is a transcriptional activator and belongs to the family of protein arginine methyltransferase. It mediates mono- and asymmetric arginine dimethylation on both histone tails and non-histone proteins. It mainly catalyzes the dimethylation at histone H3 arginine 2 (H3R2), 17 (H3R17), and 26 (H3R26). CARM1 is mainly nuclear during the G1, S, and G2 phases of the cell cycle and is cytoplasmic during mitosis, after breakup of the nuclear membrane. It is recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families and methylates histone H3 to activate transcription via chromatin remodeling. At the molecular level, CARM1-mediated histone dimethylation has been implicated in RNA transcription, pre-mRNA splicing, mRNA translation, and genome stability. It is also shown to be involved in several cellular processes, including pluripotency maintenance of embryonic stem cells, differentiation of epithelial cells, and spermatogenesis. CARM1 Undergoes automethylation at arginine 550 that enhances its transcription coactivator activity. Methylation is also required for its role in the regulation of pre-mRNA alternative splicing. It also undergoes phosphorylation at serine 216, which interferes with S-adenosyl-L-methionine binding and strongly reduces its methyltransferase activity. Phosphorylation at seine 216 is enhanced during mitosis and decreases rapidly to a very low level after entry into the G1 phase. Overexpression of CARM1 has been reported in prostate adenocarcinomas and high-grade prostatic intraepithelial neoplasia. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Cao. Z., et al. (2021). Front. Cell Dev. Biol. 9; 678282; Feng, Q., et al. (2009). J. Biol. Chem. 284(52); 36167-36174).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.